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Aberrant STAT phosphorylation signaling in
peripheral blood mononuclear cells from
multiple sclerosis patients
Ester Canto, Noriko Isobe, Alessandro Didonna, MS-EPIC Study Group, Stephen L. Hauser and Jorge R. Oksenberg*
Abstract
Background: Multiple sclerosis (MS) is characterized by increased activation of peripheral blood mononuclear cells
(PBMCs), linked to perturbations in the phosphorylation of signaling proteins.
Methods: We developed a phosphoflow cytometry protocol to assess the levels of 11 phosphorylated nuclear
proteins at baseline conditions and after cell activation in distinct PBMC populations from 41 treatment-naïve
relapsing-remitting (RR) MS subjects and 37 healthy controls, and in a second cohort of 9 untreated RRMS
patients and 10 secondary progressive (SP) MS patients. Levels of HLA-ABC, HLA-E, and HLA-DR were also
assessed. Phosphorylation levels of selected proteins were also assessed in mouse splenocytes isolated from
myelin oligodendrocyte glycoprotein (MOG)35–55-induced experimental autoimmune encephalomyelitis (EAE).
Results: Modest differences were observed at baseline between patients and controls, with general lower
phosphorylation levels in cells from affected individuals. Conversely, a dramatic increase in phosphorylated
p38MAPK and STAT proteins was observed across all cell types in MS patients compared to controls after in
vitro activation. A similar phosphorylation profile was observed in mouse lymphocytes primed in vivo
with MOG. Furthermore, levels of all p-STAT proteins were found directly correlated with HLA expression in
monocytes. Levels of phosphorylated proteins did not differ between relapsing-remitting and secondary
progressive MS patients either in baseline conditions or after stimulation. Lastly, phosphorylation levels appear
to be independent of the genotype.
Conclusion: The response to IFN-α through STAT proteins signaling is strongly dysregulated in MS patients
irrespective of disease stage. These findings suggest that the aberrant activation of this pathway could lead
to changes in the expression of HLA molecules in antigen presenting cells, which are known to play important roles in
the regulation of the immune response in health and disease.
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Background
The primary pathogenic role of inflammatory responses in
multiple sclerosis (MS) and its broadly used animal model,
experimental autoimmune encephalomyelitis (EAE), is
supported by a large body of laboratory, pathology, and
genetic data [1–4]. Furthermore, clinical-based evidence
from more than 20 years of immunotherapy firmly con-
firms that this neurodegenerative disease is at its core
autoimmune. However, the early mechanisms driving the
immune dysregulation in the periphery that lead to central
nervous system (CNS) myelin breakdown, axonal damage,
and neuronal cell death, are not fully understood. In-
triguingly, genetically determined changes in signaling
responses and activation thresholds in specific im-
mune cell lineages have been described in MS [5].
Identifying dysregulated signaling pathways in cell
compartments relevant to the disease and their rela-
tionship with genetic variance could represent a use-
ful strategy to better understand the natural history
of MS and discover new therapeutic targets.* Correspondence: Jorge.oksenberg@ucsf.edu
Department of Neurology and Weill Institute for Neurosciences, University of
California at San Francisco, Nelson Rising Lane, San Francisco, CA 94158, USA
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Perturbations of cell-specific signaling pathways can
be efficiently assessed using a flow cytometry-based
technique known as phosphoflow cytometry [6–8].
Phosphoflow cytometry measures the activation status of
key intracellular signaling molecules in response to dif-
ferent stimuli (e.g., antigen recognition through antigen
receptors, unspecific stimulations, or activation of cyto-
kine receptors), through the quantification of the phos-
phorylated forms of transcription factors or tyrosine and
serine threonine kinases, which in turn are responsible
for the downstream phosphorylation of multiple intra-
cellular targets (reviewed in [7]). Phosphoflow cytometry
has been used in the past few years to assess the activa-
tion status of cells in various autoimmune diseases such
as systemic lupus erythematosus and rheumatoid arth-
ritis [9, 10], in which changes in protein phosphorylation
have been associated with disease activity.
Abnormal levels of phosphorylated proteins belonging
to the signal transducers and activators of transcription
(STAT) family in the peripheral blood mononuclear cells
(PBMCs) of MS patients have been associated with a
number of clinically relevant phenotypes, including the
development of clinically definite MS in individuals pre-
senting a clinically isolated syndrome (CIS) [11], the de-
velopment of flares [12], and high titers of neutralizing
antibodies against interferon beta (IFN-β) [12–14]. Note-
worthy, inhibitors of the JAK/STAT pathway have shown
to ameliorate the clinical signs of EAE by means of inhi-
biting CD4 T cell differentiation toward the pro-
inflammatory Th1/Th17 subtypes [15, 16]. The analysis
of both baseline and activated levels of phosphoproteins
can provide therefore, important information to identify
disease-associated biochemical pathways that are either
abnormally upregulated or downregulated. However,
there are no studies investigating the differences in the
phosphorylation response to in vitro activators between
MS patients and healthy controls. In the present study,
we applied phosphoflow cytometry to simultaneously
measure for the first time the induced phosphorylation
response of 11 different proteins in five peripheral blood
immune cell subsets in treatment naïve, short disease
duration MS patients and matched controls. The results
show that PBMCs from MS patients have an innate pro-
pensity to heighten protein phosphorylation in response
to stimuli, in particular STAT proteins, which are found
consistently upregulated upon stimulation across all the
analyzed cell subsets of the blood.
Methods
Subjects
The study included 60 MS patients enrolled and evaluated
at the Multiple Sclerosis Center, University of California,
San Francisco (UCSF), participating in a prospective ob-
servational cohort [17]. Analysis was organized in two
groups; the first consisted of 41 relapsing-remitting (RR)
untreated MS patients and 37 gender- and age-matched
healthy controls, and the second consisted of 9 untreated
RRMS patients and 10 secondary progressive (SP) MS
patients matched by gender, age, and disease duration. In-
clusion and exclusion criteria were previously described,
but patients fulfilled the International Panel on Diagnostic
criteria for MS [18] and were untreated at the time of
blood sampling.
In addition to extensive clinical data, 4-digit resolution
HLA allele typing for HLA-A, HLA-B, HLA-C, HLA-
DRB1, and HLA-DQB1 was available for all study partici-
pants. Genome-wide single nucleotide polymorphisms
(SNPs) genotypes were available for 32 MS study partici-
pants. Using the most updated list of established non-
MHC MS-associated variants (n = 200) [19], we calculated
the overall cumulative genetic burden (MSGB) and two
specific ontological pathway genetic burdens for each
study participant: MSPBphos (risk SNPs in prioritized
genes in the protein phosphorylation ontological family)
and MSPBregphos (risk SNPs in prioritized genes in the
regulation of protein phosphorylation ontological family).
Each polygenic score was determined as the allele dose
multiplied by the reported allele effect size [19–21]. In
addition to MSGB scores, we also selected single STAT-
associated SNPs to assess individual effects of specific
variants on the regulation of phosphorylation responses.
For that purpose, we limited the search to validated MS
risk variants [19] located within 1 Mb from the STAT pro-
tein genes. Three SNPs in the proximity of STAT genes:
rs6738544 (close to STAT1 and STAT4 genes), rs1026916
(close to STAT3 and STAT5 genes), and rs701006 (close
to STAT6 gene), were identified and selected for the ana-
lysis of association with levels of phosphorylation of STAT
proteins. Genotyping data for STAT1/4 SNP was available
for 32 MS patients and 20 controls and genotyping for
STAT3/5 and STAT6 SNPs was available for 32 patients.
The Committee on Human Research at UCSF ap-
proved the study protocol. Written informed consent
was obtained from all the participants. The clinical and
demographic characteristics of the patients and controls
are shown in Table 1.
Phosphoflow cytometry and HLA assessment by flow
cytometry
We adapted and modified a previously reported protocol
[8] to simultaneously determine baseline and activated
levels of 11 phosphoproteins (Bruton’s tyrosine kinase
(Btk), Phosphoinositide phospholipase C (PLCγ), Protein
kinase B (Akt), Casitas B-lineage Lymphoma (Cbl), P38
mitogen-activated protein kinase (p38MAPK), Extracellular
Signal-regulated Kinase 1/2 (Erk1/2) and Signal Transduc-
ers and Activators of Transcription 1, 3, 4, 5, 6 (STAT1,
STAT3, STAT4, STAT5, STAT6)) by flow cytometry in five
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different peripheral blood cell types (CD4 T cells,
CD8 T cells, B cells, monocytes, and NK cells).
Briefly, 10 million cryopreserved PBMCs were thawed
and allowed to rest for 1 h at 37 °C. Then, cells were
stimulated for 15 min with H2O2 (45 mM) for Btk,
PLCγ, Akt, and c-Cbl activation in response to oxida-
tive stress, Phorbol 12-myristate 13-acetate (PMA)
(400 nM; Sigma-Aldrich) for p38MAPK and Erk1/2
activation, and human IFN-α (40,000 U/mL; Milli-
pore) or recombinant human IFN-γ (4000 U/mL;
R&D Systems) for STAT proteins activation. For base-
line levels assessment, cells were left unstimulated for
15 min at 37 °C. Cells were subsequently fixed with
formaldehyde (final concentration 1.5%) and perme-
abilized with 100% ice-cold methanol for 30 min on ice.
After washing, cells were stained for the phosphoproteins
and cell-specific markers. A representative dot plot show-
ing the gating strategy for the analysis of the different
blood cell populations and the antibodies used for staining
is detailed in Additional file 1: Figure S1. Fold changes of
protein phosphorylation were calculated as the ratio of the
mean fluorescence intensity (MFI) after stimulation over
the MFI in baseline conditions.
In a subgroup of 21 patients and 21 matched healthy con-
trols, levels of total p38MAPK, Erk1/2, STAT1, and STAT6
were assessed following the same protocol as described
above without adding any stimuli to the cells. The antibodies
used for staining are detailed in Additional file 1: Figure S1.
For the analysis of HLA-E, HLA-ABC, and HLA-DR ex-
pression, cells were stimulated with either human IFN-α
(40,000 U/mL; Millipore), recombinant human IFN-γ
(4,000 U/mL; R&D Systems) or were left unstimulated for
24 h at 37 °C. Then, cells in suspension were collected
and the adherent cells were detached with PBS-0.05%
EDTA on ice for 30 min. Cells were then washed with
PBS, blocked with Fc blocking reagent (Miltenyi Biotech,
San Diego) following the manufacturer’s protocol, and
subsequently stained with cell-specific marker antibodies
and HLA-E, HLA-ABC, and HLA-DR antibodies.
EAE induction and antigen-specific phosphoflow
Five 8-weeks-old C57BL/6 J female mice (from Jackson
Laboratories) were injected subcutaneously with 100 μg
MOG35–55 (EZBiolab), in complete Freund’s adjuvant
(DIFCO Laboratories). Mice received 400 ng of pertussis
toxin by intraperitoneal injection at day 0 and at day 2.
Five control mice were mock-injected with everything ex-
cept for the MOG peptide. All animal experiments were
conducted according to protocols approved by the local
animal welfare committee. Spleens from EAE and control
mice were harvested 15 days post immunization (dpi) and
splenocytes were isolated. Cells were stimulated with
MOG35–55 (10 μg/mL, EZBiolab) for 24 h or left unstimu-
lated. Then, splenocytes were fixed with formaldehyde
(final concentration 1.5%) and permeabilized with 100%
ice-cold methanol for 30 min on ice. After washing, cells
were stained for the phosphoproteins and cell markers
with the antibodies in Additional file 1: Figure S1.
Statistical analysis
A Wilcoxon test was used to compare phosphorylation
status between cases and controls, and t test was used to
compare phosphorylation levels between EAE and con-
trol mice. Spearman correlation coefficients were calcu-
lated to study correlations between variables. p values
less than 0.05 were considered significant. All statistical
analyses were computed using code written in R soft-
ware (r-project.org) 3.3.1 version. In order to minimize
batch effects, samples from both patients and controls
were normalized using the Generalized Feature Scaling
(GFS) method. To generate heatmaps, MFI values or
fold change values for each phosphorylated protein in
each cell type were transformed into z-scores and plotted
according to the following color code: samples with levels
of phosphorylated proteins higher than the mean are
depicted in red while proteins showing levels of phosphor-
ylated proteins lower than the mean are depicted in blue.
Results
Peripheral blood mononuclear cells from MS patients are
highly sensitive to in vitro activation
The most consistent difference observed between patients
and controls in baseline conditions was a generalized de-
crease in levels of the tested phosphorylated proteins. In
particular, the levels of phosphorylated p38MAPK were
found significantly decreased in MS patients across all cell
Table 1 Clinical characteristics of patients and controls
RRMS vs controls RRMS vs SPMS
Clinical variable Controls n = 37 RRMS n = 41 p value RRMS n = 9 SPMS n = 10 p value
Gender (female/male) 28/9 31/10 1.0 9/0 10/0 1.0
Age (years) 42.9 (10.1) 43.5 (9.6) 0.932 57.4 (8.8) 56.3 (9.6) 0.870
Disease duration (years) – 4.6 (2.6) – 23.5 (6.3) 22.7 (6.5) 0.806
EDSS – 1.8 (1.1) – 2.6 (1.2) 5.0 (1.5) 3.4 × 10− 3
Clinical characteristics of the patients and controls used for the study. Values shown as mean (standard deviation). RRMS relapsing-remitting multiple sclerosis,
SPMS secondary progressive multiple sclerosis
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types (Fig. 1, Additional file 2: Table S1). STAT1 phos-
phorylation levels were also found decreased in CD4
T cells (p = 0.014), NK cells (p = 0.002) and monocytes
(p = 2.05 × 10− 4). Furthermore, levels of phosphory-
lated STAT6 (p = 0.018, p = 0.048) were decreased,
while phosphorylated Akt was found increased in
CD8 T cells (p = 0.003) and NK cells (p = 0.001) from
MS patients compared to controls.
The different in vitro stimuli induced protein phos-
phorylation in all the analyzed cell types, both in pa-
tients and healthy controls (Additional file 3: Table
S2). However, the phosphorylation fold change in re-
sponse to the different stimuli was found increased in
patients with MS compared to controls. Specifically,
the response to oxidative stress was found signifi-
cantly increased in patients’ samples for p-Cbl (p =
0.007) and p-Akt (p = 0.017) in monocytes and CD8
T cells, respectively (Fig. 1, Additional file 3: Table
S2). Likewise, a significant increment in p-Erk1/2 (p
= 0.003) in monocytes and in Btk (p = 0.001) in B
cells was observed. Interestingly, a fold change in-
crease in phosphorylated p-p38MAPK was observed
in all cell types except CD8 T cells. Additionally, we
observed a consistent increase in phosphorylation of
STAT proteins in response to IFN-α in all cell types,
but especially strong in the NK cell population (p
value range 0.006 to 2.04 × 10− 10). Finally, the abso-
lute levels of phosphorylated STAT proteins were
found to have increased after stimulation in MS pa-
tients compared to controls (Fig. 1, Additional file 4:
Table S3).
In order to rule out the possibility that the observed
differences in the levels of phosphorylated proteins and
phosphorylation response were caused by differences in
the absolute levels of those proteins, we measured the
total levels of p38MAPK, Erk1/2, STAT1, and STAT6
(the ones that showed the most significant differences
between patients and controls) in a subgroup of RRMS
patients and controls. Age, disease duration, and EDSS
in this subset were similar to the full dataset (p = 0.709,
p = 0.294, and p = 0.871, respectively). We found no dif-
ferences in the total levels of these proteins between MS
patients and controls (Additional file 5: Table S4).
Phosphorylation response and clinical variables
Protein phosphorylation has been previously associated
with disease activity or severity in other autoimmune dis-
eases; hence, we were interested in exploring the
Fig. 1 Immune cells from MS patients show a distinct phosphorylation signature in baseline conditions and upon in vitro stimulation. PBMCs from
RRMS patients (n = 41) and healthy controls (n = 37) were either left unstimulated or activated for 15 min with H2O2 for Btk, PLCγ, Akt, and c-Cbl
activation, PMA for p38MAPK and Erk1/2 activation, and human IFN-α for STAT proteins activation. a The individual z-score transformation of the MFI
of each phosphorylated protein or the fold change of phosphorylation has been represented for each cell population in each subject of the study.
b The summary of the z-scores of the MFI of each phosphorylated protein or the fold change of phosphorylation has been represented for each cell
population in MS patients and controls. MS patients show lower levels of phosphorylated proteins in baseline conditions, and increased levels of
phosphorylated proteins and increased fold changes of phosphorylation after stimulation compared to healthy controls. Levels of phosphorylated
proteins higher than the mean are shown in red and levels of phosphorylated proteins lower than the mean are shown in blue
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correlation between levels of protein phosphorylation after
stimulation and the Expanded Disability Status Scale
(EDSS), which is a broadly used measure of disease dis-
ability in MS. We found a weak correlation between levels
of p-Erk1/2 in CD4 T cells (Spearman corr = 0.55; p =
2.9 × 10− 03) and CD8 T cells (spearman corr = 0.48; p =
1.4 × 10− 02) and EDSS, but not for any of the other
phosphoproteins analyzed. Interestingly, we observed that
activated levels of p-STAT3 and p-STAT5 in NK cells from
MS subjects positively correlate with disease duration
(r = 0.34, p = 0.035 and r = 0.43, p = 0.0075) but not
with age (r = − 0.06, p = 0.73 and r = 0.06, p = 0.73),
suggesting that changes in the susceptibility to STAT
phosphorylation might reflect a physiological mechanism as-
sociated with the disease, independent of aging. Next, we de-
termined the levels of phosphorylated proteins in a cohort
of untreated patients who had transitioned to SPMS (n = 10)
compared to a group with similar disease duration and age
that did not (n = 9). No differences were detected either in
baseline conditions or after stimulation (Additional file 6:
Table S5 and Additional file 7: Table S6).
Phosphorylation levels of STAT proteins and MS risk
genomic variants
We next assessed whether the increased phosphorylation
in STAT proteins observed in MS patients in response
to stimuli was related to the 200 genetic variants associ-
ated with MS susceptibility. We focused on STAT
proteins because of their consistent increase of phos-
phorylation observed across all cell types. For this
purpose, we first considered the correlation between
levels of all phosphorylated proteins and the MSGB,
MSPBphos, or MSPBregphos, which are weighted cumu-
lative scores that summarize the total or ontological
polygenic genetic burden of MS risk variants for each in-
dividual. No consistent correlations between these vari-
ables and protein phosphorylation were seen
(Additional file 8: Table S7 and Additional file 9: Table
S8). Likewise, when we assessed the correlation between
p-STAT proteins and individual risk SNPs located within
1 Mb from the STAT protein genes, we did not observe
a difference in levels of p-STAT proteins between the
different genotypes that could help explain the increase
observed in MS. In addition, no differences in phosphor-
ylated protein levels were observed between individuals
carrying 0, 1, or 2 copies of the HLA risk allele HLA-
DRB1*15:01 (data not shown). Overall, these results sug-
gest that the increased STAT protein phosphorylation
observed in MS patients might not be affected by the
disease risk loci, although this lack of association might
be due to the limited power in our dataset. Thus, larger
studies will be required to firmly prove or disprove an
association between variants affecting the risk of devel-
oping MS and the dysregulated signaling pathways.
Phosphorylation of STAT proteins correlates with
HLA expression after IFN-α and IFN-γ stimulation in
monocytes
Previous studies have shown that interferons modulate the
expression of major histocompatibility complex (MHC)
class I and MHC class II molecules in T cells and mono-
cytes, as well as in other cell types such as tumor cell lines
[22, 23]. This process is mediated by STAT proteins [24].
Hence, we were interested in assessing if there was an asso-
ciation between STAT protein phosphorylation levels and
the expression of classical HLA-A, B, C, and DR and non-
classical HLA-E both at baseline and after stimulation with
either IFN-α or IFN-γ. First, we observed that IFN-α in-
duces class I HLA-E and HLA-ABC expression in all cell
types independent of disease status, while it mainly induces
class II HLA-DR expression in NK cells and in monocytes
(Table 2). Similarly, stimulation with IFN-γ induces modest
increases of HLA-E and HLA-ABC expression in all cell
types, but a very strong upregulation of HLA-DR in mono-
cytes and to a lesser degree in NK cells.
In a subsequent analysis, we compared the increase in
HLA expression between MS patients and healthy
subjects in all cell subtypes. Notably, we only observed a
higher fold change in HLA-DR expression in CD8 T cells
and a higher fold change in HLA-ABC and HLA-E ex-
pression in NK cells after IFN-γ stimulation in MS pa-
tients compared to controls (Fig. 2). We also analyzed the
correlation between HLA-E, HLA-ABC and HLA-DR ex-
pression and p-STAT proteins levels and we found that in
B cells, p-STAT1 and p-STAT5 levels correlated with
HLA expression after IFN-γ stimulation while p-STAT4
negatively correlated with HLA expression. Surprisingly,
in NK cells, p-STAT3, p-STAT4 and p-STAT6 levels cor-
related negatively with HLA expression after IFN-γ stimu-
lation (Additional file 10: Table S9). On the other hand, in
monocytes, levels of phosphorylated STAT proteins were
found consistently correlated with increased HLA expres-
sion after stimulation with both IFN-α and IFN-γ (Fig. 3).
Antigen-specific response in EAE is mediated by
p38MAPK and multiple STAT proteins
The results described above showing an increased re-
sponse to activation in MS patients were generated by
challenging PBMCs with non-specific stimuli. To confirm
the observed signaling dysregulation in the context of
neuroantigen-specific responses, we analyzed the levels of
selected proteins in splenocytes isolated from MOG35–55-
induced EAE mice and re-stimulated in vitro with the
same peptide. An increase in phosphorylation of
p38MAPK was observed in B cells (p = 0.016) and CD4 T
cells (p = 0.008) of EAE mice as compared to mock
injected animals (Fig. 4), along with an increase in p-
STAT1 in all cell types following the same pattern ob-
served in human PBMCs. In addition, pSTAT4 was also
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increased after MOG stimulation in CD4 T cells of EAE
mice compared to controls (p = 0.02), consistently mim-
icking the response observed in MS patients. We also
found an increase in STAT5 phosphorylation in CD4 T
cells (p = 0.008). These results confirm the singularity
of each cell compartment in responding to activation
and show that some of the pathways that are aber-
rantly activated in the immune cells of MS patients
are also activated in an antigen-specific manner in
the EAE model.
Discussion
In the present study, we developed and optimized a
phosphoflow cytometry protocol to simultaneously
assess the activation status of multiple signaling path-
ways in cryopreserved lymphocytes isolated from well-
Table 2 Fold change of HLA expression induced by IFN-α and IFN-γ in each cell type analyzed
Fold change HLA-E
(IFN-α)
Fold change HLA-E
(IFN-γ)
Fold change HLA-ABC
(IFN-α)
Fold change HLA-ABC
(IFN-γ)
Fold change HLA-DR
(IFN-α)
Fold change HLA-DR
(IFN-γ)
B cells 1.733 1.503 1.286 1.202 0.979 1.041
CD4 T cells 1.790 1.514 1.554 1.267 0.921 1.070
CD8 T cells 1.609 1.343 1.510 1.207 0.976 1.098
NK cells 2.124 1.487 1.739 1.292 1.558 1.750
Monocytes 2.261 1.377 2.096 1.539 1.458 3.131
Mean values of fold change in HLA-E, HLA-ABC, and HLA-DR expression in different cell types of both MS patients (n = 14) and controls (n = 11) after 24 h of IFN-α
and IFN-γ stimulation
Fig. 2 HLA expression is increased in MS patients upon interferon stimulation. PBMCs from RRMS patients and healthy controls were either left
unstimulated or activated with IFN-α or IFN-γ for 24 h. Boxplots show the fold change in expression of HLA-E, HLA-ABC, and HLA-DR in CD8 T
cells and NK cells in MS patients and controls. Each dot represents a sample. IFN-γ induced a higher HLA-DR expression in CD8 T cells and HLA-E
and HLA-ABC expression in NK cells from MS patients compared to controls. Statistical differences were calculated using Wilcoxon test
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characterized, untreated MS patients. The analysis at
baseline conditions revealed a general downregulation of
phosphorylated signaling proteins in MS across all per-
ipheral cellular components, in particular p38MAPK,
with the exception of Akt and Cbl, which were found
upregulated in MS patients. Since increased p38MAPK
phosphorylation has been described in the CNS upon
EAE induction [25], and its pharmacological blockade
has shown to inhibit the differentiation of CD4 T cells
into Th17 cells, both in MS and the animal model [26,
27], our results appear counterintuitive. However, the in-
crease in p38MAPK and other phosphoproteins phos-
phorylation after in vitro stimulation was significantly
higher in MS patients compared to controls, suggesting
that immune cells from MS patients exhibit a higher
propensity to activation, independent of the baseline
levels of phosphorylated protein. Additionally, in re-
sponse to IFN-α stimulation we observed an extensive
upregulation in the levels of phosphorylated STAT pro-
teins in MS patients compared to controls across all cell
Fig. 3 Interferon-induced HLA expression correlates with STAT protein phosphorylation in monocytes. Scatterplots show the correlation between
mean fluorescence intensity (MFI) of each STAT protein and the expression levels of HLA-E, HLA-ABC, and HLA-DR after stimulation with IFN-α or
INF-γ in monocytes from MS patients and controls. IFN-α induced HLA expression in monocytes correlates with levels of phosphorylated STAT
proteins. Correlation between variables was calculated using Spearman’s rank correlation coefficient
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subsets but especially within the NK cell population,
which has been implicated in MS pathogenesis [28, 29].
GWAS have identified SNPs in the proximity of STAT
genes associated with increased risk of MS [3, 4, 21] and
genetic depletion of these genes modulates EAE devel-
opment [30–32]. Our study confirms the role of STAT
proteins, in particular of STAT1, in immune cell activa-
tion of both human cells and splenocytes from EAE
mice in response to the MOG immunogenic peptide.
Given that HLA expression can be modulated by
interferons [22, 23, 33], we were also interested in
investigating the association between increased STAT
protein phosphorylation and HLA expression in re-
sponse to interferon in MS patients and controls. Our
results show a clear correlation between levels of STAT
phosphorylation in monocytes, which are the primary
antigen presenting cells in the blood, and the levels of
HLA expression after stimulation with interferon but
not at baseline conditions. Interestingly, no consistent
correlations were found between levels of phosphory-
lated STAT proteins and HLA expression in B cells,
which are also known to participate in antigen
Fig. 4 Antigen-specific response in EAE is mediated by STAT protein phosphorylation. Splenocytes from EAE and control mice were stimulated
with MOG35–55 peptide for 24 h and levels of p-p38MAPK, p-Erk1/2, p-STAT1, p-STAT3, p-STAT4, p-STAT5, and p-STAT6 were evaluated. Boxplots
show the fold change in protein phosphorylation compared to unstimulated cells. MOG35–55 stimulation induced phosphorylation of STAT1 in all
cell types, p38MAPK in B cells and CD4 T cells, STAT5 in CD4 and CD8 T cells, and STAT4 in CD4 T cells of EAE mice but not control mice. Statistical
differences were calculated using an unpaired t test
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presentation, suggesting different regulation machineries
for HLA expression in response to interferon across cell
types. The results also indicate that monocytes are more
susceptible to activation by interferon in MS patients.
This exaggerated activation, reflected as an increased
phosphorylation of STAT proteins, would lead to an
upregulation of HLA expression in this cell type and, as
a potential consequence, a dysregulation of the immune
responses.
Two additional (negative) observations are worth
discussing. A recent study proposed that genetic risk
variants affect the activation of transcriptional factors
[5]. The increased phosphorylation response that we ob-
serve in MS patients appears not to be related to the cu-
mulative disease susceptibility variants each individual
carries either globally (MSGB), stratified by relevant
ontological pathways (MSPBphos, MSPBregphos), or the
individual risk variants in the proximity of STAT genes.
One limitation of our analysis, however, was the limited
power of the dataset and consequent impaired capacity
of detecting allelic variants effects on the endopheno-
type. Although the role of genetic variants in immune
cell activation cannot be completely discarded, other
mechanisms could explain the differential response ob-
served in MS patients. Previous studies have shown that
the levels of expression of IFN receptors (IFNAR1 and
IFNAR2) correlate with the activation of some STAT
proteins [34, 35]. We show that both IFNα and IFNγ
can regulate HLA expression, but only IFNα-induced
HLA expression correlates with STAT proteins phos-
phorylation. This could make us think that, indeed, a
differential expression of IFNAR1 and IFNAR2 in the
immune cells of MS patients could be driving the
increased activation response observed in MS. However,
this would not explain the increased phosphorylation
observed in other proteins in response to H2O2 or PMA.
This seems to indicate that changes in the levels or func-
tion of other kinases and phosphatases involved in regu-
lation of protein phosphorylation might be playing a role
in how molecules from multiple signaling cascades are
responding to stimulation.
In addition, we did not find any differences on the
protein phosphorylation profile between RRMS and
SPMS patients. Even though the number of samples
from SPMS patients and the corresponding RRMS
patients was limited, these results are in agreement with
the observed lack of association between levels of phos-
phorylated protein and EDSS. This result suggests that
the phosphorylation response in immune cells is not
associated with the severity of the disease and thus it
does not change during disease progression.
Finally, EAE has been widely used to simulate multiple
aspects of the disease. One of the main advantages of
this model resides in the a priori knowledge of the
antigen driving the autoimmune response. For that rea-
son, we were interested in analyzing the phosphorylation
profile of splenocytes from EAE mice against the MOG
peptide, which could reveal the pathways activated during
antigen-specific responses. The increased p-p38MAPK and
p-STAT levels after MOG35–55 stimulation found in EAE
mice mimics the response observed in the different human
PBMCs cell compartments and supports the role of STAT
proteins phosphorylation as previously proposed [36].
Conclusions
Our results show that immune cells from MS patients
are highly sensitive to different in vitro stimuli, especially
to IFN-α through STAT proteins signaling. This dysreg-
ulation is observed in both relapsing and progressive
clinical courses, and does not seem to be related to the
genetic variants associated with the disease. Our findings
also suggest that activation of the STAT pathway in im-
mune cells can modify the expression of HLA in mono-
cytes, which are the main antigen presenting cell in the
blood, and this could lead to changes in the regulation
of the immune response. The fact that each of the pro-
tein presents a different phosphorylation pattern in each
individual cell type, suggests that the activation re-
sponses are selectively regulated. Therefore, further work
to understand the effect of the activation of individual
pathways will need to be focused on highly homogenous
cell lineages or even single cells.
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